Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
NCT05523947 · View on ClinicalTrials.gov ↗
Study Summary
This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.
Conditions Studied
Interventions
- DRUG YH32367
Study Locations (19)
Other
- Southern Oncology Clinical Research Unit — Adelaide
- Austin Health — Melbourne
- Breast Cancer Research Centre - WA — Perth
- Blacktown Hospital — Sydney
- Gachon Gil University Medical Center — Incheon
- Korea University Anam Hospital — Seoul
- Seoul National University Hospital — Seoul
- Severance Hospital, Yonsei University Health System — Seoul
- Asan Medical Center — Seoul
- Samsung Medical Center — Seoul
- The Catholic University of Korea, St. Mary's hospital — Seoul
- Ulsan University Hospital — Ulsan
Gyeonggi-do
- CHA Bundang Medical Center — Seongnam-si
- Catholic University of Korea St. Vincent's Hospital — Suwon
- Ajou University Hospital — Suwon
Massachusetts
- Dana Farber Cancer Institute — Boston
Tennessee
- Vanderbilt Ingram Cancer Center — Nashville
Gyeongsangnam-do
- Gyeongsang National University Hospital — Jinju
North Chungcheong
- Chungbuk National University Hospital — Cheongju-si
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2022-08-26 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05523947
The ClinicalTrials.gov registry entry for NCT05523947 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yuhan Corporation, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with HER2-Positive Solid Tumor appearing as the primary indexed condition, and to 1 intervention — of which YH32367 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05523947 reports 19 study locations spanning 6 distinct geographic areas — top geographies include Other, Gyeonggi-do, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05523947 about?
NCT05523947 is a clinical study titled "Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor". This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.
What is the current status of trial NCT05523947?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 147 participants. The study started on 2022-08-26. Estimated completion is 2028-04-30.
What conditions does trial NCT05523947 study?
This clinical trial studies the following conditions: HER2-Positive Solid Tumor. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05523947?
The interventions under investigation include: YH32367 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05523947?
This trial is sponsored by Yuhan Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05523947 being conducted?
This trial has 19 study locations across Massachusetts, Tennessee, Gyeonggi-do, Gyeongsangnam-do, North Chungcheong. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.